Lupin is expecting to achieve 18 per cent growth by the end of this year from domestic business. The company’s domestic business had seen a contraction of 5 per cent in the April-June quarter. Domestic revenues had declined due to the Government’s move to cut prices of all medicines in the National List of Essential Medicines.
The company’s Indian business, which contributed 25 percent of the company’s turnover during the quarter, clocked revenue of Rs 663 crore, compared with Rs 606 crore in the corresponding period last year.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
